肿瘤免疫治疗中过继性细胞疗法的研究进展

Advances in Research on Adoptive Cell Therapy in Tumor Immunotherapy

肿瘤免疫疗法旨在利用免疫系统建立针对性的抗肿瘤免疫反应,激活肿瘤免疫细胞是免疫疗法的关键点。过继性细胞疗法是通过体外改造、扩增免疫细胞提高免疫功能,再回输患者体内以发挥抗肿瘤效应。除了已广泛应用于临床的嵌合抗原受体T细胞疗法,近年来T细胞受体-T细胞疗法、肿瘤浸润淋巴细胞疗法、嵌合抗原受体-自然杀伤细胞疗法、嵌合抗原受体-巨噬细胞疗法等新型过继性细胞疗法也开始进入临床。综述近年来过继性细胞疗法的研究进展,以期为基于该疗法进行肿瘤的免疫治疗提供参考。

Tumor immunotherapy aims to activate targeted anti-tumor immune response through the immune system.It is crucial to activate tumor immune cells for immunotherapy.Adoptive cell therapy is designed to improve immune activation ability by modifying and amplifying immune cells in vitro,which are then infused back into the patient for anti-tumor effect.In addition to CAR-T(chimeric antigen receptor T-cell)therapy,which has been widely used in clinical practice,novel therapies such as TCR-T(T cell receptor T-cell)therapy,TIL(tumor infiltrating lymphocytes)therapy,CAR-NK(chimeric antigen receptor-engineered natural killer cell)therapy and CAR-M(chimeric antigen receptor macrophage)therapy have also entered clinical trials in recent years.This article mainly summarizes recent research advances of adoptive cell therapy in the hope of providing reference for the development of tumor immunotherapy-based adoptive cell therapy.